ArticleTranslational andrology and urology2026
Identification of prognostic factors for postoperative recurrence-free survival in T2-stage renal cell carcinoma: a retrospective cohort study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T2-stage renal cell carcinoma (RCC) is associated with high postoperative recurrence risk and heterogeneous outcomes, but stage-specific prognostic factors remain insufficiently explored. This study aimed to systematically analyze the clinicopathological factors influencing postoperative recurrence-free survival (RFS) (defined as the time from surgical resection to the first occurrence of local recurrence, distant metastasis, or death from any cause) in patients with T2-stage RCC and explore reliable independent prognostic indicators for this specific subgroup. Methods: We retrospectively collected clinicopathological data and follow-up records of T2-stage RCC patients who underwent surgery at the Second Hospital of Lanzhou University from January 2018 to December 2023. Postoperative RFS was the primary endpoint. The Kaplan-Meier method was used for survival analysis and survival curve plotting; univariate and multivariate Cox proportional hazards regression models were applied to identify independent prognostic factors. Internal stability of the identified prognostic factors was evaluated using bootstrap resampling (1,000 iterations) and Harrell's concordance index (C-index). Results: A total of 182 patients were included (mean age: 55±13 years; median follow-up: 40 months). After rigorous variable screening (including collinearity elimination and biological independence assessment), five independent prognostic factors for postoperative RFS were identified: the aspartate transaminase to alanine transaminase ratio (AST/ALT ratio) [hazard ratio (HR) =3.295, 95% confidence interval (CI): 1.899-5.719, P<0.001], Fuhrman grade (HR =2.380, 95% CI: 1.412-4.012, P=0.001), systemic immune-inflammation index (SII) (HR =3.009, 95% CI: 1.567-5.776, P<0.001), sarcomatoid differentiation (HR =3.463, 95% CI: 1.981-6.054, P<0.001), and carbonic anhydrase IX (CAIX) (HR =5.425, 95% CI: 2.555-11.519, P<0.001). Internal validation showed a mean C-index of 0.835 (95% CI: 0.780-0.885), indicating good and stable discriminatory ability of the identified factors. Conclusions: The AST/ALT ratio, Fuhrman grade, SII, sarcomatoid differentiation, and CAIX are independent prognostic indicators for postoperative RFS in T2-stage RCC patients. These factors can facilitate accurate risk stratification and provide a scientific basis for formulating individualized follow-up and treatment strategies. Given the limitations of single-center retrospective design and small sample size, future large-scale prospective multicenter studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.